REAL WORLD EFFECTIVENESS OF JAK INHIBITOR UPADACITINIB IN ULCERATIVE COLITIS VERSUS CROHN’S DISEASE IN AN IBD TERTIARY CARE CENTER

Abstract

Abstract BACKGROUND Upadacitinib is a selective Janus kinase inhibitor approved for the management of Crohn’s Disease (CD) and Ulcerative Colitis (UC). AIMS To compare response to upadacitinib between patients with UC and CD in a real world tertiary care center. METHODS Retrospective cohort study of adult patients with CD vs UC seen at UCSF Colitis and Crohn’s Disease Center from 2019-2023. The primary outcome was endoscopic remission as noted in post-induction staging scope. Endoscopic remission was assessed using SES-CD and Mayo scores for CD and UC, respectively. Outcomes were assessed at 3 or 6 months after starting upadacitinib for UC and CD, respectively. Failure was considered failure to meet remission criteria, change in medications shortly after induction, or surgery. RESULTS A total of 60 patients were reviewed, 26 with Crohn’s Disease and 34 with Ulcerative Colitis, who had taken Upadacitinib and had post-induction follow up data in EHR review. 10 patients with CD achieved remission (38.5%) compared to 17 patients with UC (50%). This difference was found to be nonsignificant (P=0.38). CONCLUSION In this real-world cohort of IBD patients seen at a tertiary care center, there was no significant difference in response between patients with CD or UC.